近日，华升证券发布美中嘉和（02453.HK）深度研究报告，给予“买入“评级。核心投资亮点：美中嘉和打造“中国的MD安德森”。 美中嘉和医学技术发展集团股份有限公司成立于2008年，是参与制定我国多项放疗行业标准的唯一一家非公立机构，是国内唯一拥有质子治疗系统的国际化高端肿瘤医疗服务集团。经过十年磨一剑式的长期投资经营，公司在中国拥有5家自有医疗机构，分别是3家肿瘤医院、1家肿瘤门诊部、1家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.